Get the Stockscreener App
34.04
0.76%
-0.26
After Hours:
34.03
-0.010
-0.03%
Veracyte Inc stock is traded at $34.04, with a volume of 559.52K.
It is down -0.76% in the last 24 hours and up +5.94% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$34.30
Open:
$34.3
24h Volume:
559.52K
Relative Volume:
0.62
Market Cap:
$2.70B
Revenue:
$517.15M
Net Income/Loss:
$66.35M
P/E Ratio:
41.45
EPS:
0.8212
Net Cash Flow:
$126.63M
1W Performance:
+4.19%
1M Performance:
+5.94%
6M Performance:
-2.13%
1Y Performance:
+7.18%
1-Day Range:
$33.90
$35.19
1-Week Range:
$30.56
$35.19
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
34.04 | 2.73B | 517.15M | 66.35M | 126.63M | 0.8212 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 - BioSpace
Veracyte to Release Q1 2026 Results on May 5 - National Today
Veracyte to Release Q1 2026 Earnings on May 5 - National Today
Veracyte (NASDAQ: VCYT) awards 44,221 RSUs to Chief Dev and Tech Officer - Stock Titan
Veracyte Inc (VCYT) Stock Up 4.3% and Still Undervalued -- GF Sc - GuruFocus
Jefferies initiates coverage of Veracyte (VCYT) with buy recommendation - MSN
VCYT Initiates Coverage by Jefferies -- Price Target Set at $45 - GuruFocus
Jefferies Initiates Veracyte at Buy With $45 Price Target - marketscreener.com
Jefferies initiates Veracyte stock with buy on diagnostics growth - Investing.com UK
Jefferies initiates Veracyte stock with buy on diagnostics growth By Investing.com - Investing.com Canada
Jefferies Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $45 - Moomoo
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Wygant Jonathan - Moomoo
VCYT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Sentiment Watch: Can Veracyte Inc be the next market leaderPortfolio Gains Report & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Veracyte Inc (VCYT) Shares Down 4.29% on Apr 9 - GuruFocus
Veracyte Stock Crosses Below 200-Day Moving Average - National Today
Veracyte, Inc. (VCYT) Stock forecasts - Yahoo Finance UK
VCYT Technical Analysis & Stock Price Forecast - Intellectia AI
VCYT PE Ratio & Valuation, Is VCYT Overvalued - Intellectia AI
Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound? - MSN
Veracyte Inc (NASDAQ:VCYT) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate - ChartMill
Emerging Growth Patterns Driving Rapid Expansion in the Oncology Molecular Diagnostics Market - openPR.com
Precision Trading with Veracyte Inc. (VCYT) Risk Zones - Stock Traders Daily
Veracyte (VCYT): Needham Reaffirms "Buy" Rating with $48 Price T - GuruFocus
Veracyte (NASDAQ:VCYT) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Needham reiterates Veracyte stock rating on bladder cancer test plans By Investing.com - Investing.com South Africa
Needham reiterates Veracyte stock rating on bladder cancer test plans - Investing.com
Veracyte, Inc. (VCYT) stock price, news, quote and history - uk.finance.yahoo.com
Cathie Wood’s ARK buys OpenAI Group stock, sells Veracyte shares By Investing.com - Investing.com UK
Cathie Wood’s ARK buys OpenAI Group stock, sells Veracyte shares - Investing.com
Is Veracyte Stock a Smart Addition to Your Investment Portfolio at This Time? - Bitget
Is Veracyte Stock the Right Pick for Your Portfolio Now? - Yahoo Finance Singapore
MACD Signal: Is Veracyte Inc stock a value trap2026 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
VCYT SEC FilingsVeracyte 10-K, 10-Q, 8-K Forms - Stock Titan
Veracyte price target lowered to $45 from $50 at Guggenheim - TipRanks
Exit Recap: Is Veracyte Inc a strong candidate for buy and hold2026 Analyst Calls & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Guggenheim Maintains Buy Rating, Lowers Price Target on VCYT to $45 | VCYT Stock News - GuruFocus
Veracyte (NASDAQ:VCYT) Price Target Lowered to $45.00 at Guggenheim - MarketBeat
Guggenheim Maintains Veracyte(VCYT.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
Does Veracyte (NASDAQ:VCYT) Deserve A Spot On Your Watchlist? - Moomoo
Veracyte (NASDAQ:VCYT) Shares Down 9.2%What's Next? - MarketBeat
Vanguard disaggregates reporting; lists zero holdings in Veracyte (VCYT) - stocktitan.net
Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Volatility Watch: Is Veracyte Inc stock a top performer YTDPortfolio Return Report & Expert Approved Trade Ideas - baoquankhu1.vn
Veracyte, Inc. $VCYT Shares Sold by Nordea Investment Management AB - MarketBeat
Veracyte, Inc. $VCYT Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veracyte Inc Stock (VCYT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stapley Marc | Chief Executive Officer |
Mar 04 '26 |
Sale |
35.97 |
45,523 |
1,637,594 |
357,554 |
| Leite John | Chief Commercial Officer-CLIA |
Mar 04 '26 |
Sale |
35.19 |
5,260 |
185,083 |
107,580 |
| McGuire Annie | SVP, General Counsel |
Mar 04 '26 |
Sale |
35.55 |
6,658 |
236,725 |
94,706 |
1.41%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):